Equities Analysts Issue Forecasts for Geron FY2025 Earnings

Geron Co. (NASDAQ:GERN) – Equities researchers at B. Riley cut their FY2025 EPS estimates for shares of Geron in a research note issued to investors on Tuesday, February 18th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will earn ($0.08) per share for the year, down from their previous forecast of ($0.03). B. Riley currently has a “Buy” rating and a $3.50 target price on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron’s FY2026 earnings at $0.12 EPS.

Other equities analysts have also recently issued research reports about the stock. Needham & Company LLC increased their price objective on shares of Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. Finally, Barclays upgraded shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Geron currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.91.

Geron Price Performance

Shares of NASDAQ:GERN opened at $2.54 on Thursday. The firm’s 50 day moving average price is $3.16 and its 200-day moving average price is $3.89. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.54 billion, a PE ratio of -7.94 and a beta of 0.53.

Institutional Investors Weigh In On Geron

A number of institutional investors have recently added to or reduced their stakes in the stock. Alternative Investment Advisors LLC. grew its holdings in Geron by 13.3% during the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 2,612 shares in the last quarter. Rovin Capital UT ADV grew its holdings in shares of Geron by 26.9% in the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 3,660 shares in the last quarter. Values First Advisors Inc. grew its holdings in shares of Geron by 13.6% in the third quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 3,668 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Geron by 23.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,094 shares in the last quarter. Finally, Xponance Inc. grew its holdings in shares of Geron by 12.9% in the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 4,829 shares in the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.